Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics Stock Performance
ADAP Stock traded up $0.05 on Tuesday, reaching $2.27. The company's stock had a trading volume of 18,483 shares, compared to its average volume of 199,785. The business has a fifty day simple moving average of $1.74 and a two-hundred day simple moving average of $2.02. Adaptimmune Therapeutics has a 12-month low of $1.26 and a 12-month high of $6.86.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Rating) last announced its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). Adaptimmune Therapeutics had a negative return on equity of 93.64% and a negative net margin of 1,500.43%. The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. During the same period in the previous year, the business earned ($0.24) EPS. As a group, research analysts expect that Adaptimmune Therapeutics will post -1.18 earnings per share for the current year.